|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
61,650,000 |
Market
Cap: |
241.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.08 - $5.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Omeros is a commercial-stage biopharmaceutical company. Co. is focused on discovering, developing and commercializing small-molecule and protein therapeutics for larger-market as well as orphan indications targeting immunologic diseases. Co.'s drug candidate narsoplimab is the subject of a biologics license application pending before the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Co. has various late-stage clinical development programs in its pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A nephropathy, atypical hemolytic uremic syndrome and COVID-19.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
Total Buy Value |
$0 |
$0 |
$40,500 |
$40,500 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
10,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$64,950 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2018-07-26 |
4 |
OE |
$4.10 |
$191,900 |
D/D |
43,000 |
192,645 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2018-07-26 |
4 |
AS |
$21.53 |
$753,687 |
D/D |
(35,000) |
184,645 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2018-07-12 |
4 |
AS |
$21.48 |
$91,886 |
D/D |
(4,277) |
184,645 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2018-07-12 |
4 |
OE |
$4.10 |
$17,536 |
D/D |
4,277 |
188,922 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-05-15 |
4 |
OE |
$9.37 |
$166,898 |
D/D |
17,812 |
13,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-05-15 |
4 |
AS |
$24.95 |
$319,659 |
D/D |
(12,812) |
8,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-05-14 |
4 |
AS |
$22.45 |
$246,501 |
D/D |
(10,980) |
8,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-05-14 |
4 |
OE |
$9.37 |
$102,883 |
D/D |
10,980 |
19,480 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-01-04 |
4 |
OE |
$9.37 |
$9,370 |
D/D |
1,000 |
8,500 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2018-01-03 |
4 |
OE |
$6.05 |
$634,312 |
D/D |
70,532 |
184,645 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2018-01-03 |
4 |
AS |
$21.45 |
$1,341,226 |
D/D |
(62,528) |
176,641 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-01-03 |
4 |
AS |
$22.45 |
$22,899 |
D/D |
(1,020) |
7,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2018-01-03 |
4 |
OE |
$9.37 |
$9,557 |
D/D |
1,020 |
8,520 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2017-12-28 |
4 |
OE |
$2.45 |
$413,838 |
D/D |
142,001 |
2,026,986 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2017-08-21 |
4 |
OE |
$6.05 |
$48,400 |
D/D |
8,000 |
176,641 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-16 |
4 |
AS |
$24.95 |
$299,400 |
D/D |
(12,000) |
7,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-16 |
4 |
OE |
$9.37 |
$131,180 |
D/D |
14,000 |
19,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-15 |
4 |
AS |
$22.45 |
$269,400 |
D/D |
(12,000) |
5,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-15 |
4 |
OE |
$9.37 |
$131,180 |
D/D |
14,000 |
17,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-14 |
4 |
AS |
$19.95 |
$186,533 |
D/D |
(9,350) |
3,500 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-14 |
4 |
OE |
$9.37 |
$120,404 |
D/D |
12,850 |
12,850 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-13 |
4 |
AS |
$19.95 |
$52,868 |
D/D |
(2,650) |
0 |
|
- |
|
Jacobsen Michael A |
VP Finance and CAO |
|
2017-06-13 |
4 |
OE |
$9.37 |
$24,831 |
D/D |
2,650 |
2,650 |
|
- |
|
Cable Thomas J. |
Director |
|
2017-04-12 |
4 |
AS |
$16.49 |
$49,474 |
D/D |
(3,000) |
40,067 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2017-03-20 |
4 |
OE |
$6.05 |
$12,342 |
D/D |
2,040 |
168,641 |
|
- |
|
123 Records found
|
|
Page 3 of 5 |
|
|